Skin Cancer/Melanoma

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

A two-time cancer survivor discusses her recently-discovered pancreatic cysts.

This two-time cancer survivor and clutter-clearing author struggles more thoughtfully with clutter since cancer.

A recent survey showed that most Americans do not know what cutaneous squamous cell carcinoma is and how severe the disease can be if it advances.

A two-time cancer survivor explores her thoughts on aging.

Cancer can switch you to a different track but does not necessarily derail you, says a two-time cancer survivor.

Nine years out from breast cancer and four years out from her melanoma, this cancer survivor still combats her fatigue.

There I was with my freshly darkened skin in the mirror (after a beautiful day out in the sun). What was I thinking? Oh yeah, I wasn’t thinking.

From hereditary cancer risk among twins to study findings in squamous cell carcinoma, here’s what is making headlines in the cancer space this week.

Figuring out whether to take targeted drugs or immunotherapy can be challenging for patients with metastatic melanoma that expresses a BRAF gene mutation, but there are rules of thumb that can help.

A nine-year breast cancer survivor and five-year melanoma survivor shares her thoughts on cancer survivorship with a side of mid-life crisis.

In a talk to people affected by melanoma, Michael McGrady described reassessing his values after cancer and how it changed the course of his life.

Following surgery with medication, combining immunotherapies or targeted drugs and adding radiation to immunotherapy can improve effectiveness in treating various stages of melanoma.

With greater longevity for survivors of melanoma comes the need to treat lingering side effects and monitor for cancer recurrences.

Immunotherapy may be giving hope to people living with rare skin cancer.

The Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) – an immunotherapy agent – for the treatment of patients with resected, high-risk, stage 3 melanoma.

Here are tips for fellow cancer survivors to clear out cancer paraphernailia but keep important medical records.

Two-time cancer survivor suggests a careful approach when researching your own cancer.

A web-based intervention may help reduce harmful UV exposure and skin cancer risk in young adults, according to recent research.

The Food and Drug Administration (FDA) granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to the agency.

Young patients diagnosed with posterior uveal melanoma may have similar, if not worse, prognoses compared with the overall patient population.

Patients with BRAF wild-type advanced melanoma saw a survival benefit after treatment with Opdivo (nivolumab) compared with the chemotherapy agent dacarbazine.

The combination use of two immunotherapy agents in the first-line setting helped patients with advanced melanoma live longer compared with treatment with either drug alone.

To combat the psychological effects from a lymphedema diagnosis, patients need to be equipped with the knowledge and understanding of what the condition is and how it is treated.

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

As part of the Bristol-Myers Squibb Coast 2 Coast 4 Cancer Research ride, 109 company employees rode from Oregon to New Jersey to help raise funds for the V Foundation for Cancer Research.

The panelists acknowledged that many individuals face barriers to receiving regular skin check-ups. Some people – especially those in rural areas – may not have a dermatologist near them. And even if they do make it in to a doctor’s office for a skin check-up, they may not be checked as thoroughly as they should be.

Lynn Schuchter, M.D., discussed immunotherapy and BRAF/MEK inhibition at the Melanoma Action Coalition’s Fall Conference.

Substitute thinking "life management" instead of "time management."